Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
MDxHealth SA ADR(MDXH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MDXH
09/25/2026: MDXH (1-star) is a SELL. SELL for 5 days. Simulated Profits (-20.00%). Updated daily EoD!
MDxHealth is a commercial-stage diagnostic company that provides specialized molecular tests for prostate and other urologic cancers. Its main strength lies in a focused diagnostic portfolio and an expanding U.S. commercial platform that supports physician decision-making. The investment story centers on capturing market share through clinical evidence and broader reimbursement. However, the company faces significant competition from larger, well-capitalized diagnostics firms and carries inherent execution risks as it scales its operations toward potential profitability. It is best suited for growth-oriented investors with a high risk tolerance, who should monitor developments in reimbursement coverage and quarterly revenue growth.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential for high revenue growth but carries the execution risks of a smaller diagnostic player. |
| Momentum investor | Weak fit | Momentum indicators often require sustained, large-cap trends not typically found in this smaller-cap medical segment. |
| Value investor | Weak fit | The company's history of net losses and focus on growth make it an unsuitable candidate for traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on business expansion. |
| Low-risk investor | Weak fit | High volatility and the inherent risks of the biotechnology sector are incompatible with low-risk investment mandates. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap diagnostic stocks often experience significant price swings based on news cycles and market sentiment. |
| Valuation risk | Medium / high | Valuations are often predicated on long-term growth expectations that may be disrupted by execution failures. |
| Competition risk (diagnostics) | High | Larger incumbents with massive commercial organizations create high barriers to rapid market share gain. |
| Business quality | Medium | While the diagnostic technology is specialized, the company is still establishing the necessary scale to prove sustained profitability. |
| Dividend income | Low / none | The company does not generate the free cash flow required to support dividend payments. |
| Execution risk | High | Success depends heavily on the effective sales and marketing of diagnostic tests to urologists. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -94.74% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.93M USD | Price to earnings Ratio - | 1Y Target Price 1.8 |
Price to earnings Ratio - | 1Y Target Price 1.8 | ||
Volume (30-day avg) 11.6M shares | Beta -501643.7 | 52 Weeks Range 0.40 - 5.33 | Updated Date 09/27/2026 |
52 Weeks Range 0.40 - 5.33 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Urology Diagnostics | Revenue from test processing fees for tests like ConfirmMDx, SelectMDx, and GPS. | The company gets paid when doctors order its tests and they are processed in its labs. |
| Geography: United States | Majority of commercial revenue and test processing operations. | Most of the company's success depends on the competitive U.S. healthcare insurance and provider market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 27.7 | Enterprise Value 143.88M | Price to Sales(TTM) 0.47 |
Enterprise Value 143.88M | Price to Sales(TTM) 0.47 | ||
Enterprise Value to Revenue 1.26 | Enterprise Value to EBITDA 17.57 | Shares Outstanding 95.42M | Shares Floating 42.51M |
Shares Outstanding 95.42M | Shares Floating 42.51M | ||
Percent Insiders 22.14 | Percent Institutions 45.15 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About MDxHealth SA ADR
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2021-11-04 | CEO & Executive Director Mr. Michael K. McGarrity | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 364 | Website https://mdxhealth.com |
Full time employees 364 | Website https://mdxhealth.com | ||
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.